To date, many meta-analyses have investigated the performance of cfDNA in detecting EGFR mutation status in patients with NSCLC and only two meta-analyses evaluated also KRAS (Fan et al., 2017; Chen et al., 2020). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.